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STUDY PROTOCOL Open Access
Study protocol for the multicentre cohorts
of Zika virus infection in pregnant women,
infants, and acute clinical cases in Latin
America and the Caribbean: the ZIKAlliance
consortium
Vivian I. Avelino-Silva1,2, Philippe Mayaud3, Adriana Tami4,5, Maria C. Miranda6, Kerstin D. Rosenberger7,8,
Neal Alexander3, Luis Nacul3, Aluisio Segurado1, Moritz Pohl9, Sarah Bethencourt5, Luis A. Villar6,
Isabelle F. T. Viana10, Renata Rabello11, Carmen Soria12,13, Silvia P. Salgado14, Eduardo Gotuzzo15,
María G. Guzmán16, Pedro A. Martínez16, Hugo López-Gatell17, Jennifer Hegewisch-Taylor17,
Victor H. Borja-Aburto18, Cesar Gonzalez18, Eduardo M. Netto19, Paola M. Saba Villarroel20, Bruno Hoen21,22,23,
Patrícia Brasil11, Ernesto T. A. Marques26, Barry Rockx24, Marion Koopmans24, Xavier de Lamballerie25,
Thomas Jaenisch7,8* and the ZIKAlliance Clinical Study Group
Abstract
Background: The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a
multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites
were selected over a wide geographic range within Latin America and the Caribbean, taking into account the
dynamic course of the ZIKV epidemic.
Methods: Recruitment to the PW cohort will take place in antenatal care clinics. PW will be enrolled regardless of
symptoms and followed over the course of pregnancy, approximately every 4 weeks. PW will be revisited at delivery
(or after miscarriage/abortion) to assess birth outcomes, including microcephaly and other congenital abnormalities
according to the evolving definition of congenital Zika syndrome (CZS).
After birth, children will be followed for 2 years in the CH cohort. Follow-up visits are scheduled at ages 1–3, 4–6,
12, and 24 months to assess neurocognitive and developmental milestones. In addition, a NH cohort for the
characterization of symptomatic rash/fever illness was designed, including follow-up to capture persisting health
problems.
Blood, urine, and other biological materials will be collected, and tested for ZIKV and other relevant arboviral
diseases (dengue, chikungunya, yellow fever) using RT-PCR or serological methods. A virtual, decentralized biobank
will be created. Reciprocal clinical monitoring has been established between partner sites.
Substudies of ZIKV seroprevalence, transmission clustering, disabilities and health economics, viral kinetics, the
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potential role of antibody enhancement, and co-infections will be linked to the cohort studies.
Discussion: Results of these large cohort studies will provide better risk estimates for birth defects and other
developmental abnormalities associated with ZIKV infection including possible co-factors for the variability of risk
estimates between other countries and regions. Additional outcomes include incidence and transmission estimates
of ZIKV during and after pregnancy, characterization of short and long-term clinical course following infection and
viral kinetics of ZIKV.
Study registrations: clinicaltrials.gov NCT03188731 (PW cohort), June 15, 2017; clinicaltrials.gov NCT03393286 (CH
cohort), January 8, 2018; clinicaltrials.gov NCT03204409 (NH cohort), July 2, 2017.
Keywords: Zika, Pregnant women, Children, Cohort, Latin America, Caribbean, Risk, Congenital abnormalities,
Natural history, Arboviruses, Mosquito-borne viruses, Vector-borne viruses
Background
Identified in the 1950’s [1–3], Zika virus (ZIKV)
emerged as a critical public health issue only in 2015,
when it caused a large epidemic in Latin America and
the Caribbean that brought previously overlooked com-
plications to light [4–8]. Clusters of microcephaly and
neurological manifestations observed in late 2015,
together with recognized widespread ZIKV activity in
Brazil [9–12], prompted the World Health Organization
(WHO) to declare a Public Health Emergency of Inter-
national Concern from the 1st February until the 18th
November 2016 [13]. Despite the numerous scientific
publications on ZIKV infection produced in the past
years, crucial information on the natural history as well
as on the definition and precise risk quantification of
congenital Zika syndrome (CZS) and other developmen-
tal abnormalities are still lacking, and well characterized
prospective cohort studies are needed to clarify these.
Here we report the design of the prospective mul-
ticentre observational cohort studies conducted
within the European Commission (EC) Horizon 2020
(H2020)-funded ZIKAlliance Consortium (https://
zikalliance.tghn.org/). The Consortium as a whole in-
cludes 53 partners and is organized in eight scien-
tific and one management work packages (WPs), as
well as three cross-cutting WPs, which have been
added to organize collaboration with the other EC
H2020-funded consortia: ZikaPlan (https://zikaplan.
tghn.org) and ZikAction (http://zikaction.org/). The
cross-cutting WPs relate to the harmonization of
protocols and data sharing, to common management
and communication strategy, and to the organization
of a joint preparedness network in Latin America
and the Caribbean. In this manuscript, we focus on
the design of the clinical observational studies com-
prising the “Clinical Sciences” (WP1) and “Clinical
Biology and Immunology” (WP2) WPs. These in-
clude a Pregnant Women (PW) cohort, a Children
(CH) cohort, a Natural History (NH) cohort, and a
number of connected substudies (Fig. 1).
With this integrated prospective research approach,
we aim to i) quantify the risk of complications in CH
born to mothers infected during pregnancy, ii) identify
risk factors for these complications, and iii) describe the
NH of infection, disease and development in these CH
as well as iv) in adults. Clinical sites have been selected
over a wide geographic region bearing in mind the
evolving course of the ZIKV epidemic, allowing flexibil-
ity in enrolment by shifting towards areas with new or
ongoing ZIKV transmission. The network of clinical
sites builds on pre-existing networks for dengue virus
(DENV) studies [14], with the goal to expand to a broad
platform of collaborations and institutional partnerships
between Europe, Latin America and the Caribbean dedi-
cated to emerging diseases preparedness research. Here,
we describe the main study designs and the common
diagnostic and biobanking approach.
Methods
Study sites
The PW and CH cohort studies are carried out in se-
lected study sites across Latin America and the Carib-
bean (Fig. 2). Study sites are selected based on a)
existing or recent ZIKV transmission, combined with
ongoing collaborative research (for example the EC-
funded IDAMS-Dengue study [14]); and b) on the pro-
jection of the fringes of the mosquito vectors distribu-
tion [15]. The latter is aimed at including locations still
vulnerable for future outbreaks of ZIKV in Latin Amer-
ica at the time of the start of the study in 2016/17.
Wherever available, community seroprevalence surveys
are used to target regions where ongoing transmission is
likely [16–18].
Pregnant women (PW) cohort study
Strong evidence has been produced for a causal rela-
tionship between ZIKV infection during pregnancy and
microcephaly of the baby (as well as a range of other
congenital anomalies) through clinical-epidemiologic
studies [8, 19–21], histopathological and virologic
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demonstration of ZIKV in affected tissues [22–24], and
supportive evidence from in vitro studies and animal
infection models [25–28]. However, the quantification
of this relationship has proven difficult to measure. Co-
factors or effect modifiers have been suggested to be of
importance [29–31], but their exact role has not been
adequately measured.
We aim to estimate the absolute and relative risk of
ZIKV-associated congenital abnormalities and evaluate
the role of co-factors or effect modifiers responsible for
the variability of the risk currently observed across Latin
America and the Caribbean, including previous exposure
to other arboviruses. This will require strong support
from the laboratories linked to the enrolling sites, in
Fig. 2 ZIKAlliance study sites for the pregnant women (PW), and children (CH) cohorts (map showing environmental suitability of Zika virus
transmission according to Messina et al., 2016 [15], modified with inclusion of ZIKAlliance study sites)
Fig. 1 ZIKAlliance clinical cohorts: Pregnant Women (PW) cohort, Children (CH) cohort, and Natural History (NH) cohorts, including connected
substudies and decentralized biobank
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order to develop the expertise and tools needed to diag-
nose and monitor maternal, foetal and neonatal infec-
tions with high sensitivity and specificity.
Box 1 Key Information of the ZIKAlliance Pregnant
Women (PW) cohort study
Pregnant Women (PW) cohort (clinicaltrials.gov identifier:
NCT03188731)
Primary Objectives
1. To estimate the absolute and relative risks of congenital
abnormalities and adverse pregnancy outcomes associated with Zika
virus (ZIKV) infection during pregnancy
2. To describe the spectrum of abnormalities and adverse pregnancy
outcomes associated with ZIKV infection during pregnancy, further
characterizing the congenital Zika syndrome (CZS)
Secondary Objectives
1. To improve the diagnosis of ZIKV infection in PW and neonates
2. To measure the incidence and risk factors of ZIKV infection in PW
across a number of sites in Latin America and the Caribbean
3. To describe the clinical spectrum of ZIKV infection during
pregnancy, and determine the proportion of symptomatic and
asymptomatic infections
4. To determine the rate and risk factors of mother-to-child transmis-
sion of ZIKV (cross-cutting objective with the children [CH] cohort [see
below])
5. To evaluate the role of co-factors or effect modifiers affecting the
variability of current risk estimates for congenital abnormalities
6. To compare the risk of infant abnormalities and other adverse
outcomes between symptomatic and asymptomatic PW
7. To measure the association between time of ZIKV infection during
pregnancy and resulting abnormalities in the foetus or other pregnancy
outcomes
Inclusion/exclusion
Inclusion criteria
• Age≥ 16 years old
• Confirmed pregnancy
• Gestational age ≤ 27 weeks (extended to ≤32 weeks for inclusion in
the first month of transmission at a location with marked transmission)
• Available and willing to undergo study visits and procedures
• Written informed consent (assent form and consent by a legal
guardian if applicable)
Exclusion criteria
• Participation in another PW cohort study concerning ZIKV
Endpoints
• Congenital abnormality or adverse pregnancy outcome (according to
the evolving definition of the CZS)
Study design
Screening of PW will take place in routine antenatal
care clinics in selected sites in Latin America and the
Caribbean. PW will be enrolled regardless of ZIKV
symptoms at baseline.
PW will be followed over the course of the pregnancy
approximately every 4 weeks making use of routine
antenatal care visits and revisited at delivery (or after
miscarriage/abortion) with assessment of rash/fever illness
episodes and collection of serial blood/urine samples.
Investigations will also include a comprehensive assessment
of potential co-factors or effect modifiers for the risk of
congenital malformations in ZIKV-infected PW, such as
demographics, socio-economic status, living conditions,
TORCHS infections (Toxoplasmosis, Rubella, Cytomegalo-
virus, Herpes and Syphilis; to be tested in a subset and
according to national guidelines), HIV serostatus, previous
flavivirus infections or vaccines (e.g. DENV or yellow fever
[YF]), environmental toxins, and chromosomal abnormal-
ities. Symptomatic infections with other arboviruses (in-
cluding, but not limited to DENV, Chikungunya [CHIKV],
YF, Mayaro, Oropouche) during pregnancy will also be
evaluated as possible co-factors. PW with suspected or
confirmed ZIKV infection will be managed according to
national protocols.
The visit at birth will be considered the last visit in the
PW cohort and the starting point for the CH cohort.
Samples from placenta, amniotic fluid, cord blood,
maternal blood and urine and blood from the infant will
be collected at the birth visit. All newborns will receive a
detailed examination. Any abnormalities will be
recorded and evaluated according to the evolving
definition of the CZS [32]. Laboratory-confirmed ZIKV
infection will be defined based on a positive ZIKV quan-
titative reverse transcriptase (RT)-PCR in either body
fluid or tissue biopsy (e.G. placenta). Seroconversion be-
tween paired samples collected at different points of
time may be considered as a possible recent ZIKV infec-
tion. In view of the conflicting evidence on the specifi-
city of currently available serological assays, the final
stratification will be based on an exhaustive evaluation
of a subset of PW, which will include the use of (combi-
nations of) assays developed to increase discriminatory
power for flavivirus antibody testing [33, 34]. Over the
course of this study, both laboratory and clinical diag-
nostic criteria may undergo modifications based on re-
sults from this study and others.
Children (CH) cohort study
Infants with in utero ZIKV exposure may present with
variable degrees of abnormalities, ranging from
unapparent infection to a recognizable pattern of
structural anomalies and functional disabilities, most of
them due to nervous system damage [19, 35–37].
However, a normal examination at birth does not
guarantee normal development. Post-natal ocular ab-
normalities have been reported in infants born with
and without microcephaly [38, 39]. Late-term neuro-
logic and cognitive abnormalities for these infants are
considered to be likely, but are largely unknown. More-
over, it is unclear whether perinatal and early post-
natal infections could also lead to complications. This
is suggested by the description of immune-mediated
neurological complications among infants infected
postnatally and abnormalities among infants whose
mothers were exposed to ZIKV in the third trimester of
pregnancy [40, 41].
We aim to determine the absolute and relative risks of
developmental and neurological abnormalities in the
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first 2 years of life in CH born to women infected with
ZIKV during pregnancy.
Box 2 Key information of the ZIKAlliance Children
(CH) cohort study
Children cohort (CH; clinicaltrials.gov identifier: NCT03393286)
Primary Objectives
1. To estimate the absolute and relative risks of developmental,
neurological, ophthalmic, and auditory abnormalities during the first
2 years of life in children born to women infected with Zika virus (ZIKV)
during pregnancy compared to women not infected during pregnancy
2. To describe the spectrum of abnormalities and clinical course during
the first 2 years of life in children born to women with ZIKV, dengue
virus (DENV) Chikungunya (CHIKV) or possibly other arbovirus infections
during pregnancy
Secondary Objectives
1. To evaluate risk factors for developmental abnormalities in children
exposed to ZIKV during pregnancy
2. To describe the incidence of ZIKV infections after birth in early
childhood and evaluate the associated risks for abnormal child
development;
3. To determine the incidence of ZIKV infection in the mother after
birth and evaluate its clinical features as well as its kinetics in different
body fluids
4. To determine the rate and risk factors and effect modifiers for
congenital, perinatal and postnatal mother-to-child transmission of ZIKV
5. To describe the kinetics and evolution of infection and immune
responses to ZIKV infection in infants and children, stratified by
transmission pattern (for example in utero vs. post-natal)
Inclusion/exclusion (Fig. 3)
Inclusion criteria
• Group A: Infants born to mothers with confirmed ZIKV infection
during pregnancy
• Group B: Infants born to mothers with confirmed DENV, CHIKV or
other arboviral infection during pregnancy (detected in incident fever/
rash episodes)
• Group C: Random sample of infants born to mothers without ZIKV/
DENV/CHIKV or another arboviral infection during pregnancy (from
ZIKAlliance PW cohort), 1:1 proportion compared to groups A and B
together. The remaining children from mothers who were not infected
with any of the three arboviruses are followed in Group D (standard
visitation schedule)
• Mother-infant pairs available to undergo study visits and procedures
• Written informed consent (assent form and consent by a legal
guardian if applicable)
Exclusion criteria
• Mother aged below 16 years old
Endpoints
• Infant developmental abnormalities as assessed by neurological
examination, Ages & Stages Questionnaire® and Bayley Scales of Infant
Development
Study design
CH of women exposed to ZIKV during pregnancy, and a
subset of those not exposed, will be followed after birth
for developmental milestones (neuro-cognitive, motor,
ophthalmic, and auditory defects) and also to assess the
risk of post-natal ZIKV infection among susceptible in-
fants. We will also follow CH of women with incident
arboviral infection (including DENV, CHIKV or other
such as YF) detected in symptomatic fever/rash episodes
over the course of the pregnancy.
At delivery (last visit of PW study), investigations of the
mother will include a full blood count, serological tests for
ZIKV as well as RT-PCR-testing in blood and urine for
ZIKV. The presence of potential environmental pollutants
will be tested in a subsample of PW from appropriate bio-
logical materials. In addition, placenta and umbilical cord
tissue, cord blood, and amniotic fluid will be collected. All
biological material will be collected and stored according
to detailed SOP. TORCHS and HIV testing will be carried
out according to national guidelines and, if not available,
may be performed in stored samples for the purposes of
the study.
The investigations performed on the infant at birth will
include a standard neonatal examination comprised of
Apgar scores, anthropometry, reflexes and muscle tone,
and collection of blood via heel prick or venepuncture if
necessary. Screening tests will be carried out at birth
according to national guidelines. Additional investigations,
such as cerebral imaging or collection of cerebrospinal
fluid, will be carried out only if medically indicated.
Follow-up visits will be scheduled at ages 1–3, 4–6, 12,
and 24months to assess the infant’s development using
comprehensive neuro-developmental evaluation instru-
ments (Ages & Stages Questionnaire [ASQ-3] and Bayley
Scales of Infant Development) [42, 43]. Blood and urine
samples from the infant will be collected to test for ZIKV
infection (using RT-PCR) or seroconversion. In the
mother, we will also test blood and urine samples, with
added testing of saliva and breast milk in breastfeeding
women who test RT-PCR-positive in urine or blood. CH
with any abnormalities detected at birth or during follow-
up will be managed according to national protocols.
Natural history (NH) cohort study
The ZIKV epidemic in Latin America and the Caribbean
occurred in parallel or following a wave of CHIKV and
in the context of a high DENV incidence. Given the high
frequency of co-circulating arboviruses and their over-
lapping clinical features, the correct diagnosis of ZIKV
infection based on clinical features and antibody testing
is challenging, leading to inaccuracies in notifications
[44], and potentially impairing the implementation of ef-
fective public health interventions. The current case def-
inition for symptomatic ZIKV infections is broad [45]
and its performance has not been empirically validated.
ZIKV infection may frequently be asymptomatic or asso-
ciated with mild symptoms including low-grade fever,
itchy skin rash, conjunctivitis, arthralgia and myalgia
starting 3 to 12 days after infection; asymptomatic infec-
tion can occur in up to 80% of individuals [8, 46–49].
Neurologic complications including Guillain-Barré syn-
drome, myelitis and encephalitis [6, 11, 12, 50–53] have
been reported following ZIKV infection [30, 31] in a fre-
quency of around 1 to 5 per 10,000 adults [12].
Therefore, in the NH study, patients aged 5 years old
and older in ZIKV-endemic areas presenting to healthcare
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units with acute fever/rash illness or any other biological
evidence for ongoing ZIKV infection will be enrolled with
baseline PCR testing for ZIKV and other co-circulating ar-
boviruses depending on the local epidemiology (including,
but not limited to, DENV and CHIKV). They will be
followed daily over the acute illness period in order to ob-
tain a detailed description of the clinical features, leading
to validated case definitions. In addition, we will include
phone interviews over the first year following acute infec-
tion, in order to evaluate the incidence of complications.
Nested into the NH study will be substudies focusing on
the transmission, viral kinetics and shedding, antibody
responses, and long-term disease burden of ZIKV infec-
tion. Symptomatic PW from the PW cohort will also con-
tribute to the knowledge base of the NH study.
The aim of the NH cohort study is to generate
evidence for a more precise clinical case definition for
ZIKV infections in the context of co-circulating arboviral
infections like DENV, CHIKV or YF (vaccination) and to
better evaluate the full clinical spectrum of ZIKV infec-
tions. The enhanced clinical case definition will be eval-
uated against the current candidate WHO case
definition for ZIKV infection [54].
Box 3 Key information of the ZIKAllliance Natural
History (NH) cohort study
Natural History (NH) cohort (clinicaltrials.gov identifier:
NCT03204409)
Primary Objectives
1. To describe the clinical spectrum of disease manifestations among
individuals with febrile illness or rash (including medium-term follow-up)
and produce a validated case definition of Zika virus (ZIKV) disease
Secondary Objectives (including substudies)
1. To improve the case definition of ZIKV disease
2. To establish a precise biological description of the natural course of
the infection, with special emphasis on viral kinetics in body fluids
(Household and Viral Kinetics substudies)
3. To determine the incidence of complications and long-term seque-
lae, including severe disease presentations, chronic fatigue, ophthalmo-
logic manifestations, depression and other disabilities (Disability
Substudy);
4. To investigate the socio-economic impact associated with ZIKV in-
fection (Health Economics Substudy)
5. To describe the levels of ZIKV exposure in different epidemiological
contexts
Inclusion / exclusion
Inclusion criteria
• Age≥ 5 years
• Fever (≥37.5 °C) and/or rash for ≤5 days
• Available to undergo study visits and procedures
• Written informed consent (assent form and consent by a legal
guardian if applicable)
Exclusion criteria
• Localizing features suggesting an alternative diagnosis, e.g.
pneumonia, otitis media
Endpoints
• Clinical characterisation (signs/symptoms) and consequences of ZIKV,
dengue virus (DENV), Chikungunya (CHIKV) and possibly other arboviral
diseases
• Occurrence and duration of viral ZIKV shedding in different biologic
fluids
• Incidence of ZIKV-associated complications and disability
Methods (Continued)
• Prevalence, incidence and risk factors of ZIKV among individuals with
high or low risk of potential sexual transmission, as well as among
household contacts of index patients.
Study design
Participant enrolment for the NH study will take place
in primary care and emergency units in selected sites.
Patients aged ≥5 years old presenting with acute febrile/
rash illness in the last 5 days, and without overt signs/
symptoms suggesting alternative diagnosis will be
invited to participate.
At enrolment, demographic and clinical information
will be collected, with detailed assessment of signs/
symptoms currently included in the WHO case definition
of Zika virus disease [54], as well as symptoms of infection
with other co-circulating arboviruses such as (but not lim-
ited to) DENV or CHIKV, and basic haematology and bio-
chemistry assessments. We will also collect early blood
samples during the acute phase of illness for PCR testing
of the relevant etiological agent (concentrating on the
above-mentioned arboviruses). We will strive to detect
additional infectious agents and hence improve the
characterization of the clinical phenotype of ZIKV infec-
tion compared to other pathogens. Participants will be
followed daily (including laboratory investigations) for 2–
4 days, with an additional visit at 14 days after enrolment
to evaluate the clinical phenotype of the acute illness
period and obtain a convalescent blood sample for paired
testing. This will also allow the documentation of atypical
clinical phenotypes or complicated clinical presentations.
Patients will be contacted by phone over the following
year to capture persisting complaints or late complications.
Medical management will be carried out according to
national guidelines. We will analyse the spectrum of clinical
manifestations stratified by age, prior flavivirus immune
status, and presence of comorbidities.
Substudies
Substudies of ZIKV viral kinetics, clustering of ZIKV
transmission, impact on disability and health economics,
the potential role of antibody enhancement, and co-
infections will be connected to the NH and PW cohort
studies (Fig. 1). ZIKV transmission occurs mainly
through the bite of an infected female Aedes mosquito
[47], but transmission through blood transfusion [55–
57], sexual intercourse [58–65] and direct contact
through intact skin [66] have also been reported. ZIKV
shedding seems to occur in a range of body fluids, most
notably in male genital fluids where shedding can be
protracted for months [64, 67]. Some reports also sug-
gest shedding can also be prolonged in PW [27, 68, 69].
The frequency and duration of ZIKV shedding in
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different body fluids is unknown, as is the significance of
viral shedding for the risk of person-to-person
transmission.
Seroprevalence studies in communities
Estimates of ZIKV incidence in affected areas are often
based on notifications with insufficient laboratory
confirmation resulting in misclassifications due to other
circulating arboviruses [44]. Seroprevalence studies in
communities representing the epidemiological context of
potential participants will be underway to guide the
selection and potential relocation of sites for ZIKAlliance
cohorts over the course of the study. Populations under
investigation include groups representing a range of
socioeconomic status, environmental exposure and
susceptibility to viral sexual transmission.
Viral kinetics substudy
This substudy will enrol adults with PCR-confirmed
ZIKV identified in the cohorts in selected sites who con-
sent with a more intense follow-up including genital
samples if possible. Scheduled visits occur at days 7, 14,
21 and 28 after inclusion, then months 3, 6 and 12, with
additional collection of samples until no ZIKV is de-
tected in any sample. The primary outcome will be the
frequency and duration of ZIKV detection in blood and
other body fluids (saliva, urine, genital secretions, breast
milk) for 12 months following acute ZIKV infection, and
secondary outcomes will include potential associations
with clinical manifestations and long-term complications
or sequelae.
Household substudy
Household (HH) contacts of PW or NH participants with
confirmed ZIKV infection will be invited to participate in
in selected study sites. The main objective is to compare
the prevalence of ZIKV infection in well-defined groups,
using RT-PCR in blood and urine samples, as well as sero-
logical methods. Of special interest is the ratio of the
markers of ZIKV infection between sexual partners com-
pared to other HH contacts. In virologically-confirmed pa-
tients, we will conduct phylogenetic analysis to establish
potential concordance of ZIKV strains within and between
HH. HH contacts will be defined as any person aged 5
years and older spending > 1 week in the same HH within
1month of the index patient being identified.
Disability and health economics substudies
We will describe medium-term complications and dis-
abilities among ZIKV patients following acute infection,
and the impact of ZIKV infection on health, quality of
life and disability. We will estimate the socio-economic
burden of the disease in terms of use of family resources,
loss of income and leisure time.
Laboratory support to studies
In order to ensure comparability of inclusions across the
sites, protocols, facilities, and capacity for virologic and
serological testing will be assessed for the laboratories
linked to the clinical centres. Initial molecular testing as
well as IgM/G serology will be done locally, with
proficiency testing provided through the project. For
molecular testing, locally available protocols will be
Fig. 3 ZIKV birth cohort comprising pregnant women (PW) and children (CH) cohort studies
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used. Laboratories with insufficient performance in the
External Quality Assurance (EQA) testing are supported
by laboratory partners in the project for troubleshooting
and confirmatory testing.
Molecular testing is the gold standard for ZIKV
diagnosis and is definitive evidence for infection.
Laboratory testing will be carried out using RT-PCR (in
plasma/serum, urine, and other body fluids for ZIKV)
and serology (serum/plasma). An initial inventory of es-
sential diagnostic capacity of the laboratories associated
with clinical sites was performed, based on a previously
developed laboratory capacity and capability survey for
ZIKV diagnostics [70, 71]. Standards have been prepared
for molecular diagnostic testing [72, 73]. EQA for mo-
lecular detection of ZIKV was carried out at the start of
the study, and will be repeated at regular intervals [74].
Should lack of sensitivity be noted, the site will be con-
tacted, and test algorithms revisited, including changes
in assays or protocols. In order to harmonize laboratory
procedures, detailed standardized laboratory protocols
were developed describing the sampling frame, sample
volumes, shipping and storage conditions.
Several serological assays measuring anti-Zika virus
IgM and IgG are commercially available. From the be-
ginning of this study, all sites have been using such as-
says, for which sensitivity and specificity estimates have
ranged from 88 to 95% and 30–98%, respectively [75].
The highest estimates were generated in targeted evalu-
ation studies during the peak outbreak phase, and in
regions with a lower background frequency of prior
flavivirus exposure. The choice of the assays will be re-
evaluated on a continuous basis and may be adapted
according to new developments.
At enrolment, all participants of the PW cohort will be
tested for IgG (ZIKV, DENV) and IgM (ZIKV) antibodies
as well as via RT-PCR (as mentioned). Previous flavivirus
infection status as well as vaccinations, if applicable (i.e.
against YF or DENV) will be assessed as potential risk fac-
tors. In the case that other (arbo) viruses emerge in a cer-
tain location, they will be included in the testing panels.
Positive PCR results will be repeated for confirmation in-
cluding RNA extraction, unless both urine and blood are
tested positive initially. IgG and IgM will be repeated at
birth. Additional tests (e.g. serology) will be carried out ei-
ther batched or individually, also depending on the labora-
tory capacities at each location. In the event of confirmed
seroconversion at birth, retrospective testing of samples
will be carried out for identification of timing of infection
during pregnancy. Serologic tests will be performed using
the approved, commercial kits and in the designated la-
boratories in each country. ZIKV IgM will be tested once
every trimester of pregnancy as these antibodies may be
short-lived. The best frequency for ZIKV IgM testing will
still be subject to validation. In a subset of PW residing in
an area with documented ZIKV transmission in the previ-
ous season with detectable anti-ZIKV IgG at enrolment,
we will evaluate the specificity of the IgG assay by con-
firmatory virus neutralisation (VNT) assays with ZIKV
and DENV and other ZIKV specific serological assays,
performed in a reference laboratory. Results of the VNT
and other assays may trigger adaptations of the follow-up
schedule (e.g. for women who are no longer under risk of
ZIKV infection).
Routine laboratory facilities in each participating site
will be engaged in performing laboratory tests such as
full blood count or biochemistry. TORCHS and HIV
screening are part of the routine health investigations of
PW in many countries. Where this is not available,
TORCHS and HIV screening will be performed in
samples from all mothers who have experienced adverse
pregnancy outcomes or where congenital abnormalities
are documented. In addition, a laboratory capacity
strengthening program will be done in liaison with other
consortia, and with an European network of diagnostic
virology laboratories [70, 71, 73].
Box 4 Diagnostics used in the ZIKAlliance studies
Diagnostics
Diagnostic approach
The diagnostic approach is subjected to validation over the course of
the study. The diagnostic approach includes:
- ZIKV RT-PCR in plasma and urine at every visit for PW, CH and NH
protocols
- ZIKV IgM/IgG at PW enrolment and at birth (and at least one IgM
every trimester of pregnancy)
- ZIKV IgM/IgG at every visit of the CH cohort (both mother and child)
and in paired samples in participants of the NH study
- Dengue virus (DENV) IgG at enrolment in a subset (possibly using
new platforms and/or VNT for the assessment of past infection status)
- RT-PCR for DENV and CHIKV in addition to ZIKV in symptomatic
participants
Harmonisation of diagnostics
An EQA for molecular detection of ZIKV was performed at the start of
the study and will be repeated at regular intervals to assess the quality
of the currently used molecular test systems for ZIKV detection in the
ZIKAlliance diagnostic laboratories. This includes:
- An inventory of essential diagnostic capacity in the laboratories
associated with clinical sites, based on previously developed capacity,
and a capability survey for ZIKV diagnostics
- Detailed standardized laboratory protocols describing the sampling
frame, sample volumes, shipping and storage conditions
- Standards have been prepared for molecular diagnostic testing in the
laboratories associated with clinical sites in order to assess sensitivity/
specificity issues
If issues in the precision or accuracy of diagnostic tests are noted, the
site is contacted for revision of test algorithms, including changes in
assays or protocols.
Data management and biobanking
Participants will be assured that all information
generated in this study will remain confidential. All
data (including clinical, laboratory and genetic data)
will be stored in password-protected databases. Per-
sonal identifier information will be linked to stored data
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or samples only by a protected Master List (pseudony-
mization). This list will be kept under lock locally and
will not be shared outside the study staff at the local
partner site. No identifying information will be trans-
ferred between sites or to the central database. A gov-
ernance board including members from all partners has
been defined to coordinate the use and potential shar-
ing of data and samples.
Electronic web-based case report forms (CRFs) have
been developed using REDCap [76]. An electronic data
entry interface was set up with the option of online
data entry using a tablet device. Patient records will be
entered as pseudonymized records (by use of a study
identification number), not allowing the personal iden-
tification of patients. Clinical data and locally per-
formed laboratory results will be entered directly to the
electronic database. If initial data collection is per-
formed in paper CRFs, data entry will be performed in
a REDCap electronic CRF that mirrors the layout of the
paper form.
Privacy and data safety will be ensured by a secured
backup server and restricted access, also accommodating
different levels of data access for participant identifiable
information. Upon entry, data will automatically be
validated across the entire patient record to fit the
specific protocol requirements (plausibility and range
checks). Data queries and source data verification
requests will be generated and relayed back to each
participating site for correction. A virtual, decentralized
biobank will be created with an inventory of which
samples will be available and where, how they will be
stored, and what (raw) laboratory data will be associated.
Samples will be stored locally, and a governing body
created to ensure access and respond to requests for
samples. The collection and storage of biological
specimens will be regulated by SOP that are accessible
to all partners.
Data analysis
Because of the exploratory nature of the analysis, we did
not conduct an exact sample size calculation. However,
some power assessments were performed. For our
purposes, we only consider microcephaly, because the
variability with regard to the frequency of microcephaly is
considerably smaller than that of other congenital
abnormalities currently included in the CZS definition.
Based on estimates of the Latin American Collaborative
Study on Congenital Malformations (ECLAMC) [77], we
assume a baseline risk of 0.025% for microcephaly in
children born to ZIKV-uninfected mothers. For mothers
ZIKV-infected during pregnancy, we assume a probability
of microcephaly between 0.25 and 6% (relative risks be-
tween 10 and 240) [19, 20, 37, 78–81]. Furthermore, we
assume that the probability of a ZIKV infection during
pregnancy ranges between 5 and 30%. With a sample size
between 5000 and 6000 we can detect, with 80% power
and significance level α = 0.05, a relative risk of 20 when
the probability of ZIKV infection is 10% or higher, and a
relative risk of 30 when this probability is 5% or higher.
PW study
Data analysis will be carried out according to a pre-
specified statistical analysis plan. The characteristics of the
PW included will be assessed in a descriptive analysis, tak-
ing into account the grouping of the PW by ZIKV infec-
tion status. Possible differences between the infection
groups will be detected by appropriate measures of loca-
tion and corresponding tests (e.g. t-test, chi-square test,
Wilcoxon rank-sum test). The primary endpoint will be
any congenital abnormality or adverse pregnancy out-
come, based on the emerging definition of the CZS [32].
Any congenital abnormality will be assessed at birth but
may be updated if an abnormality only becomes apparent
later in the neonatal period. In a first step, the primary
endpoint will be analysed by a chi-square test. Next, a gen-
eralised mixed model will be fitted which contains prede-
fined basic variables. The model will be investigated and
modified by a stepwise back- and forward variable selec-
tion of the fixed effects. The region (represented by the
local partner site or by a group of sites) will be included as
a random effect in the model and will account for the het-
erogeneity between different regions. Sites may be aggre-
gated based on geographical proximity in case of data
sparseness. Interaction effects between two variables will
only be included if there is a clinical rationale. We will
present odds ratios as results of the generalised mixed
model. Throughout the analyses, we will use α = 0.05 as
significance level.
CH study
The primary endpoint in the CH study will be the
detection of any developmental abnormality within
2 years of birth. The children in the study are born to
women from the PW study or to mothers with proven
ZIKV infection during pregnancy. The two-year follow-
up brings up the practical restriction of drop-outs as
right censoring. Consequently, the primary endpoint
will be analysed with survival analysis techniques. Pre-
defined basic variables on the outcome will be included
in a Cox model with region as a random factor. Specific
developmental abnormalities, which are only measured
at one follow-up visit, will be evaluated by mixed logis-
tic models, containing the respective variables, with re-
gion as a random effect as above.
NH study
The NH study will be carried out at a subset of the sites
including participants who experience acute rash/fever
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illness, suggesting arboviral aetiology. The sample size will
depend on the local epidemiology. The statistical analysis
will be largely descriptive and informed by prior studies of
arboviral rash and febrile illness [14, 82]. The prospective
nature of the study will be used to describe the trajectory
over time of signs and symptoms, and hence further
define the case definitions of arbovirus infections,
including ZIKV.
Harmonisation, clinical monitoring, ethics, and
dissemination
The multicentre cohort studies were built on standardized
common protocols as well as a series of SOP to ensure
systematic and homogenous execution of clinical and
laboratory study procedures and sampling. Harmonisation
of protocols for clinical cohorts as well as diagnostic
algorithms has been ongoing between members of the
ZIKAlliance consortium and other currently active
research programs, funded for example by the EC or by
the National Institutes of Health (NIH). The benefit of
this is that patients can be enrolled and studied outside of
ZIKAlliance with compatible protocols, which were made
publicly available [83], and a pooled dataset may later be
analysed for the maximum benefit.
Clinical monitoring is integrated into the programme of
work from the outset, ensuring compliance with Good
Clinical Practice (GCP) standards. The studies are
conducted in accordance with the International Conference
on Harmonisation - GCP guidelines. A reciprocal clinical
monitoring network was set up between the partners of the
Consortium as part of preparedness and capacity building.
The observational studies outlined here are conducted
in accordance with the principles of the Declaration of
Helsinki, the Nagoya protocol, GCP and relevant local
regulations. All procedures employed in the clinical and
related laboratory studies comply with local and
international legislations regarding research involving
human subjects, biobanking, and shipping of specimens.
The protocols, amendments, consent and assent forms
have been submitted to the relevant Research Ethics
Committees at each study site, and to relevant
regulatory authorities for written approval.
In the case of a clinical episode suggestive of ZIKV,
the national standard of care and visitation schedule will
be followed. The study team is in close contact with
national authorities and will inform the surveillance
teams about trends of confirmed infections per site.
Unexpected incidental findings (not related to ZIKV or
other arboviral infections) may occasionally be identified
in individual patients in the course of the clinical study.
The patient and/or parent/guardian will be informed,
and with their consent, a referral will be made to an
appropriate clinic or health facility for further
investigation or longer-term follow-up.
Study results will be fed back to participants through
periodic reports, and relevant results will also be
communicated to healthcare professionals and health
authorities. Scientific dissemination will not make use of
professional writers and publications resulting from the
study will use prevailing authorship eligibility guidelines
[84]. It will be stated that the EC has no role on study
design, data collection, analysis, interpretation of results,
manuscript writing or decision to publish resulting
reports.
Discussion
After 2018, ZIKV transmission is projected to be low in
the major urban areas of Latin America [85] until
susceptibles have built up after approximately 10 years
[5]. In the meantime, the results of these large cohort
studies will provide better risk estimates for birth defects
and other developmental abnormalities associated with
ZIKV infections including possible co-factors that ex-
plain the variability of risk estimates currently seen be-
tween the Northeast of Brazil and other countries and
regions. The ZIKAlliance Consortium covers a broad
geographic region in Latin America and the Caribbean
in order to represent the different environmental and
demographic conditions that may influence the develop-
ment and outcome of the ZIKV epidemic. These data
will help decision-makers to allocate prevention and
health care resources according to severity and impact
of the epidemic. In addition, the results will provide a
historical baseline for future intervention trials, should a
vaccine or therapeutics become available and be tested
without a control arm, as has recently been done in
Ebola vaccine trials [86].
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